insights_auto
Nega LGND oshdi 2,31%?
Batafsil oʻrganishchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
301,81Â US$
arrow_upward
+2,31%(+6,81) 1K
301,81Â US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 9-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoLGND tikeri uchun statistika yaratilmoqda...
Ochish
294,79Â US$
Yuqori
304,78Â US$
Past
294,32Â US$
Bozor kapitali
6,02Â mlrd
Oʻrtacha hajm
247,38Â ming
Hajmi
183,05Â ming
P/E koeffitsiyenti
32,10
52 haftalik eng yuqori
326,63Â US$
52 haftalik eng past
175,89Â US$
Aksiya boʻyicha daromad
9,40Â US$
Beta
1,06
Muomaladagi aksiyalar
19,94Â mln
Xodimlar soni
47
Ochish
294,79Â US$
Yuqori
304,78Â US$
Past
294,32Â US$
Bozor kapitali
6,02Â mlrd
Oʻrtacha hajm
247,38Â ming
Hajmi
183,05Â ming
P/E koeffitsiyenti
32,10
52 haftalik eng yuqori
326,63Â US$
52 haftalik eng past
175,89Â US$
Aksiya boʻyicha daromad
9,40Â US$
Beta
1,06
Muomaladagi aksiyalar
19,94Â mln
Xodimlar soni
47
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
2 kun oldin
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
https://www.dars.gov.et/
·
2 hafta oldin
Ligand Pharmaceuticals (LGND) Edges Higher as Shares Trade Near $287 - ETF AUM Growth
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc haqida
CEO-
Xodimlar soni47
Asos solingansen 1987
Bosh ofislarJupiter, Florida, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytligand.com